News
IFRX
2.345
+1.52%
0.035
Weekly Report: what happened at IFRX last week (1202-1206)?
Weekly Report · 4d ago
Weekly Report: what happened at IFRX last week (1125-1129)?
Weekly Report · 12/02 09:21
Weekly Report: what happened at IFRX last week (1118-1122)?
Weekly Report · 11/25 09:19
InflaRx initiated with a Buy at Lucid Capital
TipRanks · 11/19 12:00
Positive Outlook for InflaRx: Regulatory Milestones and Promising Pipeline Drive Buy Rating
TipRanks · 11/19 06:56
Weekly Report: what happened at IFRX last week (1111-1115)?
Weekly Report · 11/18 09:19
InflaRx Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Dow Jones · 11/15 19:26
HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target
Benzinga · 11/15 19:16
LifeSci Capital Reaffirms Their Hold Rating on InflaRx (IFRX)
TipRanks · 11/15 18:35
InflaRx N.V. Receives Positive CHMP Opinion for Marketing Authorization of GOHIBIC for COVID-19 Linked Acute Respiratory Distress Syndrome Treatment
Barchart · 11/15 17:04
InflaRx Buy Rating: Promising Developments and Market Opportunities for Gohibic
TipRanks · 11/15 14:55
InflaRx receives positive CHMP opinion for SARS-CoV-2-induced acute respiratory distress treatment
Seeking Alpha · 11/15 14:05
InflaRx Gets EMA Nod for COVID-19 Treatment
TipRanks · 11/15 13:30
InflaRx receives positive CHMP opinion for GOHIBIC for SARS-CoV-2-induced ARDS
TipRanks · 11/15 12:55
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
Barchart · 11/15 06:51
InflaRx’s Strategic Advancements and Robust Financial Health Support Buy Rating
TipRanks · 11/13 07:07
InflaRx Reports Q3 2024 Financial Results and Progress
TipRanks · 11/12 04:00
LifeSci Capital Keeps Their Hold Rating on InflaRx (IFRX)
TipRanks · 11/11 12:06
InflaRx’s Promising Market Potential and Financial Stability Justify Buy Rating
TipRanks · 11/11 11:25
Weekly Report: what happened at IFRX last week (1104-1108)?
Weekly Report · 11/11 09:21
More
Webull provides a variety of real-time IFRX stock news. You can receive the latest news about Inflarx through multiple platforms. This information may help you make smarter investment decisions.
About IFRX
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.